<img height="1" width="1" style="display:none;" alt="" src="https://dc.ads.linkedin.com/collect/?pid=412980&amp;fmt=gif">
Microbion.jpg

    Microbion Corporation
    Novel compounds for resistant infections

    Microbion is a clinical-stage pharmaceutical company developing a novel class of compounds for the treatment of resistant and difficult to treat infections. MBN-101, our first therapeutic candidate, has demonstrated in vitro broad spectrum, anti-bacterial efficacy against a broad range of pathogens, including multiple priority pathogens or “superbugs” identified by the US Centers for Disease Control and Prevention (CDC). In addition, MBN-101 also has demonstrated the ability to prevent and eradicate microbial biofilms. The dual action of antimicrobial / anti-biofilm activity has the potential to become a first-in-class, best-in-class clinical approach to treating serious and life-threatening infections.

    http://www.microbioncorp.com/about/index.htm

    BACK TO PRESENTING COMPANIES